Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular mordibity in type 1 diabetic patients

European Journal of Endocrinology

Volumn 154, Issue 1, 2006, Pages 75-81

  Rasmussen, Lars Melholt ^b   Tarnow, Lise ^a   Hansen, Troels Krarup ^b   Parving, Hans Henrik ^a,c   Flyvbjerg, Allan ^b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; OSTEOPROTEGERIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE DURATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; MORBIDITY; MULTIVARIATE ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEX DIFFERENCE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; GLYCOPROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 32844472729     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02049     Document Type: Article

References (28)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Tarpley J, Derby P, Lee R & Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
2. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ & Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 1260-1268.
3. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL & Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 489-494.
4. Fu M, Zhang J, Lin YY, Zhu X, Willson TM & Chen YE. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochemical and Biophysical Research Communications 2002 294 597-601.
5. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X & Chen YE. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Letters 2002 521 180-184.
6. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA & Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. Journal of Biological Chemistry 2000 275 20959-20962.
7. Schoppet M, Al Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT & Hofbauer LC. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2004 89 4104-4112.
8. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research 2004 95 1046-1057.
9. Olesen P, Ledet T & Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005 48 561-568.
10. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P & Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003 32 681-686.
11. Browner WS, Lui LY & Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism 2001 86 631-637.
12. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B & Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1024-1028.
13. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE & Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. European Journal of Endocrinology 2003 149 39-42.
14. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S & Parving HH. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995 44 489-494.
15. Blackburn H, Keys A, Simonson E, Rautaharju P & Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960 21 1160-1175.
16. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bulletin of World Health Organisation 1962 27 645-658.
17. Rose GA & Blackburn H. Cardiovascular survey methods. Monogram Series of World Health Organisation 1968 56 1-188.
18. Feldt-Rasmussen B, Dinesen B & Deckert M. Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scandinavian Journal of Clinical and Laboratory Investigations 1985 45 539-544.
19. Mortensen JB & Rodbro P. Comparison between total and renal plasma clearance of [51Cr] EDTA. Scandinavian Journal of Clinical and Laboratory Investigations 1976 36 247-249.
20. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K & Fukagawa M. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. American Journal of Kidney Diseases 2002 39 525-532.
21. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG & Rosen CJ. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. Journal of Clinical Endocrinology and Metabolism 2002 87 4273-4279.
22. Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee HJ, Lee MS, Lee ZH & Koh GY. RANKL regulates endothelial cell survival through the phosphatidylinositol 3(-kinase/Akt signal transduction pathway. FASEB Journal 2003 17 2163-2165.
23. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R & Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. American Journal of Hypertension 2002 15 1101-1108.
24. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K & Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002 106 1192-1194.
25. Khosla S, Arrighi HM, Melton LJ, Atkinson EJ, O'Fallon WM, Dunstan C & Riggs BL. Correlates of osteoprotegerin levels in women and men. Osteoporosis International 2002 13 394-399.
26. Bernstein CN, Sargent M & Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflammatory Bowel Disease 2005 11 325-330.
27. Resnick HE & Howard BV. Diabetes and cardiovascular disease. Annual Review of Medicine 2002 53 245-267.
28. Lehto S, Niskanen L, Suhonen M, Ronnemaa T & Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 978-983.